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ABSTRACT
Survival following anthracycline-based chemotherapy remains poor among 
patients with most T-cell lymphoproliferative disorders. This may be attributed, at 
least in part, to cell-autonomous mechanisms of chemotherapy resistance observed in 
these lymphomas, including the loss of important tumor suppressors and the activation 
of signaling cascades that culminate in the expression and activation of transcription 
factors promoting cell growth and survival. Therefore, the identification of novel 
therapeutic targets is needed. In an effort to identify novel tumor dependencies, 
we performed a loss-of-function screen targeting ≈500 kinases and identified polo-
like kinase 1 (PLK-1). This kinase has been implicated in the molecular cross-talk 
with important oncogenes, including c-Myc, which is itself an attractive therapeutic 
target in subsets of T-cell lymphomas and in high-grade (“double hit”) diffuse large 
B-cell lymphomas. We demonstrate that PLK-1 expression is prevalent among these 
aggressive lymphomas and associated with c-myc expression. Importantly, PLK-1 
inhibtion with the PLK-1 inhibitor volasertib significantly reduced downstream c-myc 
phosphorylation and impaired BRD4 binding to the c-myc gene, thus inhibiting c-myc 
transcription. Therefore, volasertib led to a nearly complete loss of c-myc expression 
in cell lines and tumor xenografts, induced apoptosis, and thus warrants further 
investigation in these aggressive lymphomas.
www.impactjournals.com/oncotarget/         Oncotarget, 2017, Vol. 8, (No. 70), pp: 114474-114480
INTRODUCTION
Progression-free survival following anthracycline-
based multi-agent chemotherapy remains poor among 
patients with most T-cell lymphoproliferative disorders 
and high-risk subsets of aggressive B-cell lymphomas. 
This may be attributed, at least in part, to cell-autonomous 
mechanisms of chemotherapy resistance observed in 
these lymphomas, including the loss of important tumor 
suppressors and the activation of signaling cascades 
that culminate in the activation of transcription factors 
that instigate the expression of genes that not only 
promote cell growth and survival, but also confer 
resistance to chemotherapy. Among cutaneous T-cell 
lymphomas (CTCL), for example, primary refractory 
disease is anticipated and treatment with multi-agent 
chemotherapy regimens is not recommended for most 
patients. While the mechanisms conferring chemotherapy 
resistance are likely multifactorial, including both cell-
autonomous and non-cell-autonomous mechanisms, the 
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T-cell transcription factor GATA-3 is highly expressed 
in many of these lymphomas and was recently shown 
to mediate chemotherapy resistance [12]. The most 
common peripheral T-cell lymphoma in North America, 
designated by the World Health Organization (WHO) as 
“not otherwise specified”, includes a distinct subset that 
highly expresses GATA-3 and its gene targets. Much like 
GATA-3+ CTCL, this subset of PTCL, NOS is associated 
with a high rate (>50%) of primary refractory disease 
and poor survival following conventional chemotherapy 
and is molecularly characterized by the expression of 
c-Myc related genes [1, 7, 12]. Unfortunately, median 
overall survival for patients with relapsed/refractory 
PTCL who are not candidates for high-dose therapy and 
autologous stem-cell transplantation remain poor, as the 
responses achieved with conventional and novel salvage 
agents are rarely complete or durable. The development 
of novel and effective therapies for primary refractory 
and chemotherapy resistant T-cell lymphomas remains an 
unmet clinical need. Therefore, the identification of novel 
therapeutic targets is needed.
RESULTS AND DISCUSSION
In an effort to identify novel tumor dependencies 
in these lymphomas, we performed a loss-of-function 
(“Achilles heel”) screen targeting ≈500 kinases in a well 
characterized GATA-3+ CTCL cell line [1–4]. Aurora 
kinase A (AURKA) and its downstream target polo-like 
kinase 1 (PLK-1) were both identified as “hits” in this 
screen. These related kinases regulate mitotic entry and 
have been implicated in the molecular cross-talk with 
important oncogenes, including c-Myc [5, 6], which have 
been previously implicated in GATA-3+ T-cell lymphomas 
[7], and in high-risk subsets of diffuse large B-cell 
lymphomas. Furthermore, these kinases are frequently 
dysregulated in human cancers [8], and AURKA is a 
previously identified target in the T-cell lymphomas [9], as 
the selective AURKA inhibitor alisertib is associated with 
an overall response rate of ≈30% in these lymphomas [10]. 
Therefore, we sought to pharmacologically investigate 
the role of PLK-1 in these lymphomas using the selective 
PLK-1 inhibitor volasertib [11]. 
A library of lentiviruses expressing ~3200 shRNAs 
targeting ~501 human kinases was utilized to perform 
an “Achilles heel” screen in MyLa cells. This CTCL 
cell line was chosen as a model in this high-throughput 
screen as GATA-3 confers resistance to chemotherapy 
in a cell-autonomous manner in these cells, as observed 
in other cutaneous and peripheral T-cell lymphomas 
[1, 12]. Three independent experiments of shRNA-
mediated kinase knockdown were performed, and the 
effect of kinase knockdown on cell viability determined. 
Only kinase-specific shRNAs consistently showing 
≥80% inhibition of cell viability were considered for 
further interrogation. 
Multiple shRNA targeting two related kinases, 
Aurora A (AURKA) and Polo-like kinase 1 (PLK-1), 
were identified in our loss-of-function screen and 
satisfied our a priori selection criteria (Figure 1A). 
PLK-1, a highly conserved serine/threonine kinase that 
is overexpressed in many human cancers, promotes 
cell cycle progression upon AURKA-dependent 
phosphorylation. This finding is relevant, as the AURKA 
inhibitor alisertib has demonstrable activity in T-cell 
lymphomas [10], and a PLK-1 inhibitor (volasertib) 
is clinically available [11]. Furthermore, our loss-of-
function screen identified the RhoA associated kinase 
ROCK2 (Figure 1A and inset), a downstream PLK-1 
substrate regulating cytokinesis via phosphorylation 
of regulatory myosin light chain [13]. Therefore, we 
sought to pharmacologically validate these findings. 
A significant reduction in cell viability was observed in 
MyLa cells treated with volasertib (IC50 <50 nM; Figure 
1B–1D), culminating in PARP and caspase cleavage 
(Figure 1E), consistent with apoptotic cell death. We have 
previously demonstrated that T-cell receptor engagement 
promotes the growth and survival of malignant T cells 
ex vivo, and confers resistance to chemotherapy [12]. 
Therefore, primary malignant T cells (Sezary cells, 
n = 2) were purified and cultured ex vivo with anti-CD3/
CD28 microbeads, and viability determined in volasertib 
(or DMSO) treated cells (Figure 1F). A significant 
reduction in cell viability was observed in these primary 
samples treated with volasertib. A recently performed 
screen for dual kinase-bromodomain inhibitors identified 
volasertib as a potent BRD4 inhibitor [14]. Therefore, 
volasertib may be best classified as a dual bromodomain 
(BRD4) and kinase (PLK-1) inhibitor. This is pertinent, 
as bromodomain-containing BET proteins (including 
BRD4) transcriptionally regulate the expression of 
key oncogenes, including c-myc. Furthermore, PLK-1 
directly phosphorylates c-myc (serine 62, Figure 1A 
inset), promoting c-Myc stability. As c-myc is associated 
with chemotherapy resistance in aggressive T- and B-cell 
derived non-Hodgkin lymphomas (NHL), we sought 
to examine the extent to which volasertib impaired 
c-myc transcription and phosphorylation in MyLa 
cells. In accordance with its newly described role as a 
bromodomain inhibitor, volasertib significantly impaired 
BRD4 binding to a previously described c-myc enhancer 
(Figure 2A), leading to a commensurate inhibition in 
c-myc transcription (Figure 2B). PLK-1 inhibition with 
volasertib led to impaired c-myc phosphorylation at 
serine 62 (Figure 2C). Therefore, volasertib’s dual role 
as a BRD4 and PLK-1 inhibitor apparently converges 
on c-myc. To investigate this further in vivo, MyLa 
xenografts were generated in immunodeficient mice 
and treated with volasertib (or vehicle control). A rapid 
reduction in tumor volume was observed in volasertib 
treated mice (Figure 2D), such that only 4 (out of 10) 
tumors remained observable at the time of study 
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termination (Figure 2D, inset) in volasertib-treated mice. 
A significant loss of c-myc expression was observed in 
these tumors (Figure 2E).
Given these findings, we sought to examine 
the extent to which PLK-1 is expressed in aggressive 
T- and B-cell derived NHL. Among the T-cell lymphomas, 
6–25% of CTCL (n = 134) and 11–58% of PTCL subtypes 
(n = 90) expressed PLK-1 (Figure 3A). Consistent with 
previous observations, among CTCL cases, PLK-1 
expression was more highly expressed in tumor stage disease 
[15]. The increased PLK-1 expression in ALCL and AITL 
compared with that observed in PTCL, NOS is consistent 
with the results observed in a phase I study with the PLK-1 
inhibitor BI-2536 [16]. In this study, both ALCL patients 
achieved a complete remission, whereas a single (out 
of 3) PTCL, NOS patients achieved a partial remission. 
Among B-cell lymphomas, PLK-1 expression was most 
prevalent in DLBCL and high grade (“double hit”) B-cell 
lymphomas (HGBCL) with c-myc (and Bcl-2 and/or Bcl-6) 
translocations, as determined by FISH (Figure 3A–3B). To 
further explore a correlation between PLK-1 and c-myc 
expression, a large cohort of DLBCL biopsies (n = 138) 
was analyzed. Our analysis demonstrated that c-myc and 
PLK-1 expression were strongly correlated (R2 = 0.16, 
p < 0.0001), as >80% of c-myc+ cases expressed PLK-1 
(Figure 3C). Among “double-hit” B-cell lymphomas, 76% 
were positive for PLK-1 expression (n = 38; Figure 3C). 
PLK-1 significantly impaired cell viability (Figure 4A), 
induced PARP cleavage (Figure 4B), and significantly 
impaired c-myc expression in a broad spectrum of 
T- and B-cell lymphoma cells (Figure 4B). In summary, 
PLK-1 is a novel therapeutic target in aggressive T- and 
Figure 1: (A) Loss of function shRNA library screening plotted against the viability of MyLa cell line for each shRNA target. Selected 
kinases which decreased the viability by 80% (dotted line) are highlighted. MyLa was chosen as a model in this high-throughput screen 
as GATA-3 confers resistance to chemotherapy in a cell-autonomous manner in these cells, as observed in other cutaneous and peripheral 
T-cell lympohmas. Three independent experiments were performed and the effect of kinase knockdown on cell viability was determined 
by MTT assay, and normalized to non-targeting shRNA controls, as described [12]. (B–E) MyLa cells were treated with volasertib at the 
concentrations indicated; (B) Cell viability was measured by CellTiter Glo reagent assay from Promega Corporation, WI. (C) Apoptosis 
evaluated by Annexin V/propidium iodide incorporation. (D) Cell viability at 24 and 48 hours measured with CellTiter Glo assay. 
(E) PARP, caspase 8, and caspase 3 cleavage examined by immunoblotting. (F) Apoptosis following volasertib treatment was examined in 
two primary T-cell lymphoma samples (TCL1 and TCL2) by Annexin V/PI incorporation. 
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B-cell derived NHL, including those for which c-myc is 
an important oncogenic driver. Dual PLK-1 and BRD4 
bromodomain inhibition warrant further investigation in 
these aggressive NHL.
MATERIALS AND METHODS
shRNA library screening
The MISSION® LentiExpress™ Human Kinases 
(Sigma-Aldrich, cat#: SHX001) is a panel of lentiviruses 
expressing ~3200 shRNAs targeting ~501 human kinases. 
MyLa was chosen as a model in this high-throughput 
screen as GATA-3 confers resistance to chemotherapy 
in a cell-autonomous manner in these cells, as observed 
in other cutaneous and peripheral T-cell lympohmas 
[1, 12]. Three independent experiments were performed 
and the effect of kinase knockdown on cell viability was 
determined by MTT assay, as previously described, and 
normalized to non-targeting shRNA controls [12]. Only 
kinase-specific shRNAs consistently showing ≥80% 
inhibition of MyLa cell viability were considered for 
further interrogation. We elected, a priori, to prioritize 
these “hits” using the following criteria:1) at least one 
other kinase present in the same pathway was flagged 
and 2) a pharmacologic agent targeting a hit (or a related 
pathway) is clinically available. 
Antibodies and reagents
The following antibodies were used: PLK-1 
(208G4), PARP (D64E10), Caspase 3 (5A1E), Caspase 8 
(1C12), c-myc (D3N8F) and phospho-c-myc S62 (E1J4K), 
all from Cell Signaling Technologies, MA. Immunoblotting 
was performed, as previously described [1, 12]. Viability 
assays were performed using CellTiterGlo reagent and 
Annexin V/propidium iodide staining. Volasertib was 
obtained from Selleckchem.
Nuclear/cytoplasmic cell fractionation
Nuclear fractions were extracted from cell 
pellets per protocol (NE-PER Nuclear & Cytoplasmic 
Figure 2: (A) MyLa cells were treated with volasertib and BRD4 binding to the c-myc locus examined by Chromatin immunoprecipitation 
assay (ChIP). (B) MyLa cells were treated with volasertib and c-myc gene expression was examined by quantitative real-time PCR. 
(C) C-myc phosphorylation following volasertib (Vola) treatment (overnight) in MyLa cells was examined by immunoblotting. 
(D) MyLa cells (2 × 106) were injected subcutaneously in immunodeficient NSG mice. Upon tumor engraftment, volasertib (30 mg/kg) or 
vehicle control (DMSO) were injected intraperitoneally in 50 µL total volume (n = 10/group). Tumors were measured and mice humanely 
euthanized 4 days later. (E) Expression of c-myc examined by immunohistochemistry from representative samples of tumor xenografts 
with or without volasertib treatment. 
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Figure 3: (A) (Left) Representative images of PLK-1 expression (lower panel) in selected cases of B-cell lymphomas (follicular 
lymphoma – FL and diffuse large B-cell lymphoma – DLBCL), cutaneous T-cell lymphoma (CTCL), and peripheral T-cell lymphomas 
(angioimmunoblastic T-cell lymphoma- AITL, anaplastic large cell lymphoma – ALCL and peripheral T-cell lymphoma non-otherwise 
specified – PTCL NOS). Upper panel show corresponding hematoxylin and eosin (H&E) stains for each case. (B) Graphic representation 
of the percentage of cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphomas (PTCL) and B-cell lymphomas (B-cell) positive 
for PLK-1. The number of nuclei expressing PLK-1 was determined and a z-score of 1, corresponding to ≥20% of nuclei, selected as the 
optimal cut-off. Cases with ≥40% c-myc expression were scored positive, as previously described [13]. (C) Graphic representation of the 
average percentage of lymphoma cells expressing PLK-1. DLBCL cases were divided into three groups according to the percentage of 
c-myc positive lymphoma cells observed by immunohistochemistry. Cases of high grade (“double hit”) B-cell lymphomas (HGBCL) are 
also included. 
Figure 4: (A) Survival of different B-cell and T-cell lymphoma cell lines upon treatment with indicated doses of Volasertib at 72 hrs. 
(B) Treatment with volasertib (24 hours) induces PARP cleavage and decreases total c-myc expression in the indicated lymphoma cell 
lines. From left to right: diffuse large B-cell lymphomas (DLBCL), anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma 
(CTCL) and, peripheral T-cell lymphomas non-otherwise specified (PTCL-NOS). Protein expression was evaluated by immunoblotting. 
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Extraction Reagents, Thermo Scientific), fixed in 16% 
formaldehyde, and chromatin fragmented by sonication. 
Diluted chromatin was immunoprecipitated using isotype 
control (IgG) or anti-BrD4 antibodies (Abcam) and 
Protein G Dynabeads. Following reversal of crosslinks 
and RNaseA/proteinase K digestion, immunoprecipitated 
DNA was purified using PCR purification kit, quantified 
by Nanodrop, and c-myc transcripts quantified by qPCR. 
Animal studies
Mouse studies were approved by the University 
Committee on Care and Use of Animals (UCUCA). 
Sample size for animal experiments was based on previous 
publications performing similar experiments, ensuring 
that a sufficient sample size was selected to confidently 
assess statistical significance. Treatment allocation was 
randomized, and all animals in a given experiment were 
included for analysis. MyLa cells (2 × 106) were injected 
subcutaneously in immunodeficient NSG mice. Upon 
tumor engraftment, volasertib (30 mg/kg) or vehicle 
control (DMSO) were injected intraperitoneally in 50 µL 
total volume (n = 10/group). Tumors were measured and 
mice humanely euthanized 4 days later.
Immunohistochemistry
Formalin fixed, paraffin sections were cut at 
5 microns and rehydrated to water. Heat induced epitope 
retrieval was performed with FLEX TRS High pH 
Retrieval buffer (6.1) for 20 minutes. After peroxidase 
blocking, the antibody PLK1 rabbit monoclonal (208G4, 
Cell Signaling Technologies, MA) was applied at a 
dilution of 1:100 at room temperature for 60 minutes. The 
EnVision + Rabbit HRP System was used for detection. 
DAB chromagen was then applied for 10 minutes. 
Slides were counterstained with Harris Hematoxylin for 
5 seconds and then dehydrated and coverslipped. The 
number of nuclei expressing PLK-1 was determined and 
a z-score of 1, corresponding to ≥20% of nuclei, selected 
as the optimal cut-off. Cases with ≥40% c-myc expression 
were scored positive, as previously described [13].
Statistical analysis
Comparisons between groups were evaluated 
using a two-tailed Student t-test and all p-values <0.05 
considered statistically significant. Event-free survival 
was summarized with Kaplan-Meier plots using JMP6 
software and comparisons made with the log-rank test.
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